Sep 2026
CD20 targeted nanomedicine enhances anti-tumor immunity in diffuse large B-cell lymphoma by activating cGAS/STING pathway.
Despite the emergence of immunotherapies, the treatment of diffuse large B-cell lymphoma (DLBCL) remains challenging. This is mainly attributed to the immunosuppressive properties of the tumor microenvironment (TME), which limit the achievement of durable therapeutic responses. High expression of Polo-like kinase 4 (PL...
Zuofei Chi, Nan-Nan Xu, Ying Sun et al.
· Cancer Letters · 0 citations